Translating the Latest Data for More Durable Anti-VEGF Therapies to Treat nAMD in Clinical Practice
This American Academy of Ophthalmology collection of activities provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD).
Click on the activities below to explore valuable insights and clinical decision-making around:
Therapy selection based on patient characteristics and disease progression
Individualized dosing strategies and treatment intervals
Monitoring response and adjusting therapy to reduce treatment burden